Vendor Intelligence Report: Diju Peptides Wellness and Co

Published 3 Jul 2026. 25-page investigative report on who is behind Diju Peptides Wellness and Co: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, Diju Peptides Wellness and Co records 3 passes and 1 fail, for an overall pass rate of 75%. That evidence is narrow rather than catalog-wide: every Finnrick-tested sample is Tirzepatide. Diju is therefore a cautious Tirzepatide-only consideration when the vial can be matched to current independent testing and a batch-specific COA; the same record does not support Retatrutide, NAD+, copper peptides, SNAP-8, or skincare claims.

The strongest investigative finding is not a hidden corporate filing but a public-facing contradiction. Diju has moved from a social seller into a live .ph WordPress storefront with JotForm ordering, bank-deposit payment, Lalamove/LBC delivery terms, and a Viber transaction route. The site markets a physician-recommended, doctor-backed weight-loss experience while its legal pages disclaim therapeutic claims, FDA approval, and medical liability.

The buyer-risk profile is also channel-specific. A named doctor appears in Diju’s attribution stack, public celebrity promoters drive demand, and a DTI-registration lead remains unresolved at primary-source level. The file supports a Philippines-facing retail operation much more strongly than the directory’s China location, and it resolves the LN Peptides confusion as sample-attribution noise rather than proof of a shared supply chain.

Inside the full report:

  • Appendix A laboratory data and methodology-divergence charts for Diju’s Tirzepatide record
  • Website captures covering the homepage, safety page, terms, success stories, and order-delivery policy
  • Side-by-side analysis of “doctor-backed” marketing versus “not FDA approved” and “Research Use Only” legal language
  • Operator and promotion-network review covering TikTok, Viber, celebrity social posts, media coverage, and unverified code leads
  • Regulatory and registration checks across FDA, SEC, DTI, PDR, Halal/Kosher, Lazada, Shopee, and enforcement records
  • Brand-verification guidance for official channels, batch COAs, copycat exposure, and the LN Peptides correction trail

Risk assessment

  • Tirzepatide batch-verification and source-authenticity risk — high: Tirzepatide has 4 Finnrick tests (3 pass / 1 fail; 78.68%), but social pricing sits roughly 75–80% below named Philippines providers and no integrated batch-specific COA verification was shown.
  • Unverified regulatory and certification claims — high: Marketing repeats FDA/PDR/Halal/Kosher-style claims, while Diju’s Terms say compounds are not FDA approved and no Diju Philippines FDA registration was found for the injectable line.
  • Retatrutide investigational-product risk — high: Diju promotion lists Retatrutide, an investigational unapproved compound in the field record, with no Diju-specific Finnrick tests.
  • Brand-confusion and order-attribution risk — medium: Social/Viber/JotForm ordering lacks integrated lot tracking; Rona Samson-Tai reported transformation-photo misuse by other brands, and Finnrick corrections reassigned samples first entered as Diju.
  • Clinical-marketing and liability-disclaimer conflict — medium: The website markets physician-recommended, doctor-backed weight loss while legal terms disclaim therapeutic claims, FDA approval, and medical liability.